Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Fulcrum Therapeutics, Inc.

< Previous 1 2 3 Next >
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Second Quarter 2024 Financial Results Conference Call and Webcast on Wednesday, July 31, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Present at the 31st Annual FSHD Society International Research Congress
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate in the Goldman Sachs’ 45th Annual Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for First Quarter 2024
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC SNY
Fulcrum Therapeutics Enters into a Collaboration and License Agreement with Sanofi for the Development and Commercialization of Losmapimod in Facioscapulohumeral Muscular Dystrophy
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC SNY
Fulcrum Therapeutics to Participate in Upcoming May Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Publication of Results from Phase 2b Clinical Trial of Losmapimod in Facioscapulohumeral muscular dystrophy (ReDUX4) in The Lancet Neurology
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host First Quarter 2024 Financial Results Conference Call and Webcast on Monday, May 13, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Cantor Virtual Muscular Dystrophy Symposium
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Appoints Patrick Horn M.D., Ph.D., as Chief Medical Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Leerink Partners Global Biopharma Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Fourth Quarter and Full Year 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on Tuesday, February 27, 2024, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at Upcoming November Investor Conferences
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Third Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Host Third Quarter 2023 Financial Results Conference Call and Webcast on Tuesday, November 7, 2023, at 8:00 a.m. ET
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare Conference
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
FDA Lifts Clinical Hold on Fulcrum Therapeutics’ FTX-6058 for Sickle Cell Disease
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Announces Recent Business Highlights and Financial Results for Second Quarter 2023
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
Fulcrum Therapeutics Appoints Chief Financial Officer
From Fulcrum Therapeutics, Inc.
Via GlobeNewswire
Tickers FULC
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.